A model of tumor‐immune system interactions with healthy cells and immunotherapies
- 28 November 2021
- journal article
- research article
- Published by Wiley in Mathematical Methods in the Applied Sciences
- Vol. 45 (5) , 2852-2870
Abstract
A mathematical model of the tumor–immune system interactions is presented. The model includes the primary cell populations involved in CD4+ T cells mediated regression of the tumor, that is, tumor cells, CD4+ T cells, anti‐tumor cytokines, CTLA‐4 molecules, and normal cells. Our study reveals that host cells together with cytokines are key features in driving tumor dynamics. The malignant tumor can be completely suppressed if the tumor growth rate is small and the host cells are more competitive. No treatments are needed in this scenario as tumor cells are driven to extinction by host cells. We examine various immunotherapies of either T cells, anti‐tumor cytokines, anti‐CTLA‐4, or a combination of these to study their effectiveness. For the tumor with a medium growth rate and a moderate competitive ability to host cells, numerical simulations show that the host cells impel the tumor cells to demise due to battle with the normal cells and the effective jointed treatment strategy.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (108‐2115‐M‐126‐001)
This publication has 28 references indexed in Scilit:
- Therapeutic cancer vaccines: are we there yet?Immunological Reviews, 2010
- Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanomaJournal of Theoretical Biology, 2010
- How Normal Cells Can Win the Battle for Survival Against Cancer CellsPLOS Biology, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- CD4 cells can be more efficient at tumor rejection than CD8 cellsBlood, 2007
- Primary Antitumor Immune Response Mediated by CD4+ T CellsImmunity, 2005
- The dynamics of an optimally controlled tumor model: A case studyMathematical and Computer Modelling, 2003
- Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 CellsJournal of Experimental Medicine, 2003
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- Minutes: Mutants of Drosophila autonomously affecting cell division rateDevelopmental Biology, 1975